Quick Answer
Galmed Pharmaceuticals Ltd. reported Research And Development Expense of $4.87 million for the year ending 2025.
- Galmed Pharmaceuticals Ltd. showed an increase of +63.6% in Research And Development Expense from 2024 to 2025.
- This data is from Galmed Pharmaceuticals Ltd.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Galmed Pharmaceuticals Ltd.'s Research And Development Expense has grown by 99.5%.
- Historical annual values: Fiscal year 2025: $4.87 million | Fiscal year 2024: $2.98 million | Fiscal year 2023: $3.57 million | Fiscal year 2022: $13.00 million | Fiscal year 2021: $27.22 million | Fiscal year 2020: $26.08 million | Fiscal year 2019: $18.18 million | Fiscal year 2018: $8.31 million | Fiscal year 2017: $9.65 million | Fiscal year 2016: $14.27 million | Fiscal year 2015: $7.63 million | Fiscal year 2014: $6.66 million | Fiscal year 2013: $7.21 million | Fiscal year 2012: $2.44 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: